PRAME immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation.
Fiche publication
Date publication
janvier 2022
Journal
Human pathology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CRIBIER Bernard
Tous les auteurs :
Fattori A, de la Fouchardière A, Cribier B, Mitcov M
Lien Pubmed
Résumé
The histopathological assessment of diagnostically ambiguous melanocytic proliferation remains one of the biggest challenges in the dermatopathology field. PRAME (Preferentially expressed Antigen in MElanoma) immunostaining has been shown highly specific for distinguishing unequivocal malignant melanocytic proliferation from benign ones. Knowledge on its utility for evaluating ambiguous melanocytic neoplasms remains limited.
Mots clés
PRAME, ambiguous melanocytic proliferation, immunohistochemistry, melanoma
Référence
Hum Pathol. 2022 Jan 3;: